Hofbauer / Anker / Inui Pharmacotherapy of Cachexia

Erscheinungsjahr 2005
ISBN: 978-1-4200-4895-7
Verlag: Taylor & Francis
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 608 Seiten

Although a wealth of information can be found scattered throughout periodicals and research papers, tracking down the most effective treatment for a heterogeneous syndrome such as cachexia can be problematic. Edited by experts in the field, with contributions from a multidisciplinary panel, Pharmacotherapy of Cachexia is the first book devoted solely to the treatment of cachexia with a focus on pharmacotherapeutic aspects.

The book discusses the various aspects of the syndrome and compares and contrasts its diverse treatment options. It explores the topic from a theoretical and practical perspective and provides an overview of currently available and future treatment. The first half of the book includes coverage of pathophysiology, associated diseases, and general therapeutic aspects. The subsequent sections devoted to pharmacotherapy cover drugs in clinical use, drugs in research and development, and the final section focuses on potential future advancements.

Numerous internationally recognized specialists have contributed chapters on the various aspects of cachexia to this book. Their critical evaluation of pathophysiological mechanisms, clinical features, and therapeutic options make it a valuable source of information on all aspects of this serious and life-threatening condition. Expert editorial guidance ensures minimal repetition of information and uniform presentation. Addressing the multiple disease processes associated with cachexia in an organized and useful way, the book is a comprehensive reference for the management of this recalcitrant and hard-to-treat syndrome.

Zielgruppe

Clinical researchers who are engaged in clinical trials of ways to manage cachexia in patients with each of the disorders associated with it.

Autoren/Hrsg.

Hofbauer, Karl G.

Anker, Stefan D.

Inui, Akio

Nicholson, Janet R.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Ernährungsmedizin, Diätetik

Inhaltsverzeichnis

PATHOPHYSIOLOGY OF CACHEXIA
Malnutrition and Cachexia, C.G. Goncalves, A.L.C. Campos, J.C.U. Coelho, S. Suzuki, and M.M. Meguid
Anorexia: Central and Peripheral Mechanisms, S. Perboni, G. Mantovani, A. Inui, and Y. Takimoto
Skeletal Muscle Atrophy and Hypertrophy, D.J. Glass
Skeletal Muscle Apoptosis in Cachexia and Aging, A.J. Dirks and C. Leeuwenburgh
Neurohormonal Factors, A.L. Clark
Cytokines and the Pathophysiology of Skeletal Muscle Atrophy, V.E. Baracos

DISEASES ASSOCIATED WITH CACHEXIA
Diseases Associated with Cachexia: Cancer, R.J.E. Skipworth, M. Dahele, and K.C.H. Fearon
Cachexia Associated with AIDS, K. Berneis and K. Utech
Rheumatoid Cachexia, L.A. Coleman
Chronic Kidney Disease, B. Lindholm, J. Axelsson, O. Heimbürger, A.R. Qureshi, T. Cederholm, and P. Stenvinkel
Cardiac Failure, P.A. Poole-Wilson
Chronic Obstructive Pulmonary Disease, A.M.W.J. Schols
Cachexia in Older Persons, J.E. Morley

GENERAL THERAPEUTIC ASPECTS
Treatment Goals, A.J.S. Coats
Nutritional Treatment of Cachexia, C. Falconnier and U. Keller

DRUGS IN CLINICAL USE
Appetite Stimulants, M. John
Cardiac Cachexia - Drugs in Clinical Use, S. Strassburg and S.D. Anker
ß2-Adrenergic Agonists in the Treatment of Muscle Atrophy, C.P. Lambert, E.Y. Uc, and W.J. Evans
Androgens, Anabolic Steroids, and Glucocorticoids, L. Harle, S. Basaria, and A.S. Dobs
Growth Hormone, P.V. Carroll
Anti-Inflammatory Agents in Cancer Cachexia, M.P. Davis

DRUGS IN RESEARCH AND DEVELOPMENT
The Yin and Yang of IGF-1 and Ghrelin, R.G. Clark
Erythropoietin -A Novel Therapeutic Option for Cachectic Patients, P. Ponikowski, E.A. Jankowska, and W. Banasiak
Statins, S. von Haehling and S.D. Anker
Xanthine Oxidase Inhibitors and Insulin Sensitizers, W. Doehner
Tumor Necrosis Factor Inhibitors in the Management of Cancer-Associated Weight Loss Syndrome, S. Patiyil and A. Jatoi

FUTURE DRUG TARGETS
Central Pharmacological Targets, D.L. Marks
The Ubiquitin-Proteasome Pathway, M. Brink
Peripheral Signaling Pathways Involved in Muscle Loss, S. Possekel, T. Meier, and M.A. Ruegg
Perspectives and Outlook, K.G. Hofbauer, S.D. Anker, A. Inui, and J.R. Nicholson